Madrid

• A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastat … Ended recruitment
  2023-509867-26-00 1 2024-10-14 Advanced/metastatic solid tumor
• Efficacy and safety of oral minoxidil in women with hormone-imbalanced hair loss Ended recruitment
  2023-503383-17-01 5 2024-10-10 Female androgenetic alopecia
• A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho … Ended recruitment
  2024-511304-16-00 4 2024-10-10 Newly Diagnosed Advanced Stage Follicular Lymphoma
• Randomized and multicentre Phase II study of FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) alone or in combination with hepatic chemoe … Ended recruitment
  2024-517782-16-00 4 2024-10-10 Colorectal cancer and metastatic disease limited to the liver with bad
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• A phase Ib, open-label, ascending dose study with step-up doses to assess safety, tolerability, and pharmacokinetics of PIT565 in participan … Ended recruitment
  2023-510025-14-00 3 2024-10-08 Systemic Lupus Erythematosus
• An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Pa … Ended recruitment
  2024-511212-24-00 9 2024-10-07 Advanced solid tumors
• A Phase 3 Single-arm Study of UGN-103 for the Treatment of LG IR NMIBC. Ended recruitment
  2023-507261-25-00 5 2024-10-03 Nonmuscle Invasive Bladder Cancer
• A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep … Ended recruitment
  2023-506717-21-00 9 2024-10-02 Breast Cancer
• A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Ended recruitment
  2023-503714-77-00 4 2024-10-01 Advanced Non-Small Cell Lung Cancer
• EFFICACY AND SAFETY OF CROMOGLYCATE AS A NEW SYMPTOMATIC TREATMENT IN PATIENTS WITH MULTIPLE SCLEROSIS Ended recruitment
  2023-507541-29-00 4 2024-10-01 Multiple sclerosis
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)
• Ph2 Study of MK-3475A in Hematologic Malignances in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refra … Ended recruitment
  2024-510969-42-00 4 2024-09-30 Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapse
• A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) Ended recruitment
  2023-507655-30-00 5 2024-09-27 Obesity
• A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended recruitment
  2023-503692-24-00 5 2024-09-25 Cutaneous Lupus Erythematosus
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No … Ended recruitment
  2023-510279-80-00 4 2024-09-25 Prurigo nodularis
• PROSPER: clinical Phase 2 study to test how safe and effective is a new medicine called FNP-223 to slow disease progression of progressive s … Ended recruitment
  2023-510366-28-00 4 2024-09-25 Progressive supranuclear palsy (PSP)
• A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Ra … Ended recruitment
  2022-502269-13-00 4 2024-09-24 Glioma
• A Phase 1/2 Study of MK-2870 plus EV plus Pembrolizumab in la/mUC Ended recruitment
  2023-506387-14-00 7 2024-09-24 Advanced Urothelial Carcinoma
• A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Ended recruitment
  2024-511038-11-00 4 2024-09-24 advanced prostate cancer
• A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended recruitment
  2023-507851-31-00 5 2024-09-23 Immunoglobulin A Nephropathy (IgAN)
• ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Ended recruitment
  2023-509716-29-00 9 2024-09-23 Solid Tumors, Colorectal Cancer and Breast Cancer
• AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous … Ended recruitment
  2024-511195-33-00 3 2024-09-23 Gastrointestinal tract, biliary tract, or pancreatic cancers with homo
• A Phase 2a Study of Efinopegdutide in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis Ended recruitment
  2024-510923-20-00 4 2024-09-16 Metabolic Dysfunction-Associated Steatohepatitis

Showing 1,825–1,848 of 3,550 trials